CLINICAL_TRIALS
trial_result
· 2022-07-27
Clinical Trial Update: A Study of Brexanolone for Acute Respiratory Distress Syndrome (ARDS) Due to Coronavirus Disease 2019 (COVID-19) [Phase 3]
Summary
Phase 3 trial of brexanolone for ARDS due to COVID-19 was terminated with results posted in 2022.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sage Therapeutics | Conditions: Acute Respiratory Distress Syndrome, COVID-19 | Phase 3 | Status: TERMINATED | Results posted: 2022-07-27